<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39354098</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>01</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>04</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Cytokine landscape in hospitalized children with multisystem inflammatory syndrome.</ArticleTitle><Pagination><StartPage>22803</StartPage><MedlinePgn>22803</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">22803</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-73956-x</ELocationID><Abstract><AbstractText>The etiology of multisystem inflammatory syndrome in children (MIS-C), frequently observed following COVID-19 infection, remains elusive. This study unveils insights derived from cytokine analysis in the sera of MIS-C patients, both before and after the administration of intravenous immunoglobulin (IVIG) and glucocorticosteroids (GCS). In this study, we employed a comprehensive 45-cytokine profile encompassing a spectrum of widely recognized proinflammatory and antiinflammatory cytokines, as well as growth factors, along with other soluble mediators. The analysis delineates three principal cytokine-concentration patterns evident in the patients' sera. Pattern no.1 predominantly features proinflammatory cytokines (IL-6, IL-15, IL-1ra, granulocyte-macrophage colony-stimulating factor (GM-CSF), tumor necrosis factor α (TNFα), C-X-C motif chemokine ligand 10 (CXCL10/ IP-10), and IL-10) exhibiting elevated concentrations upon admission, swiftly normalizing post-hospital treatment. Pattern no. 2 includes cytokines (IL-17 A, IL-33, IFNγ, vascular endothelial growth factor (VEGF), and programmed death ligand (PD-L1)) with moderately elevated levels at admission, persisting over 7-10 days of hospitalization despite the treatment. Pattern no. 3 comprises cytokines which concentrations escalated after 7-10 days of hospitalization and therapy, including IL-1α, IL-1β, IL-2, IL-13, platelet-derived growth factor AA/BB (PDGF AA/BB). The observed in cytokine profile of MIS-C patients showed a transition from acute inflammation to sustaining inflammation which turned into induction of humoral memory mechanisms and various defense mechanisms, contributing to recovery.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Siemińska</LastName><ForeName>Izabela</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Clinical Immunology, Institute of Paediatrics, Faculty of Medicine, Jagiellonian University Medical College, Wielicka 265, Krakow, 30-663, Poland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Veterinary Sciences, University Center of Veterinary Medicine JU-AU, University of Agriculture in Kraków, al. Mickiewicza 24/28, Krakow, 30-059, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Bukowska-Strakova</LastName><ForeName>Karolina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Clinical Immunology, Institute of Paediatrics, Faculty of Medicine, Jagiellonian University Medical College, Wielicka 265, Krakow, 30-663, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Surmiak</LastName><ForeName>Marcin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Jagiellonian University Medical College, Skawinska 8, Krakow, 31-066, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ptak</LastName><ForeName>Katarzyna</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Paediatrics, Institute of Paediatrics, Faculty of Medicine, Jagiellonian University Medical College, Wielicka 265, Krakow, 30-663, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Szymońska</LastName><ForeName>Izabela</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Paediatrics, Institute of Paediatrics, Faculty of Medicine, Jagiellonian University Medical College, Wielicka 265, Krakow, 30-663, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olchawa-Czech</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Paediatrics, Institute of Paediatrics, Faculty of Medicine, Jagiellonian University Medical College, Wielicka 265, Krakow, 30-663, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mól</LastName><ForeName>Nina</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Paediatrics, Institute of Paediatrics, Faculty of Medicine, Jagiellonian University Medical College, Wielicka 265, Krakow, 30-663, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Błyszczuk</LastName><ForeName>Przemysław</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Clinical Immunology, Institute of Paediatrics, Faculty of Medicine, Jagiellonian University Medical College, Wielicka 265, Krakow, 30-663, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanak</LastName><ForeName>Marek</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Jagiellonian University Medical College, Skawinska 8, Krakow, 31-066, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baran</LastName><ForeName>Jarek</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Clinical Immunology, Institute of Paediatrics, Faculty of Medicine, Jagiellonian University Medical College, Wielicka 265, Krakow, 30-663, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwinta</LastName><ForeName>Przemko</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Paediatrics, Institute of Paediatrics, Faculty of Medicine, Jagiellonian University Medical College, Wielicka 265, Krakow, 30-663, Poland. przemko.kwinta@uj.edu.pl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siedlar</LastName><ForeName>Maciej</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical Immunology, Institute of Paediatrics, Faculty of Medicine, Jagiellonian University Medical College, Wielicka 265, Krakow, 30-663, Poland. maciej.siedlar@uj.edu.pl.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>19/WFSN/2020</GrantID><Agency>Ministry of Science and Higher Education in Poland</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016756">Immunoglobulins, Intravenous</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000705967">pediatric multisystem inflammatory disease, COVID-19 related</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018746" MajorTopicYN="Y">Systemic Inflammatory Response Syndrome</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="Y">Cytokines</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016756" MajorTopicYN="N">Immunoglobulins, Intravenous</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002673" MajorTopicYN="N">Child, Hospitalized</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Cytokines</Keyword><Keyword MajorTopicYN="N">Intravenous immunoglobulins (IVIG)</Keyword><Keyword MajorTopicYN="N">Multisystem inflammatory syndrome in children (MIS-C)</Keyword></KeywordList><CoiStatement>The authors declare no competing interests. No financial or non-financial benefits have been received or will be received from any party related directly or indirectly to the subject of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>7</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>7</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>23</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39354098</ArticleId><ArticleId IdType="pmc">PMC11445419</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-73956-x</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-73956-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Riphagen, S., Gomez, X., Gonzalez-Martinez, C., Wilkinson, N. &amp; Theocharis, P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 395, 1607–1608 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7204765</ArticleId><ArticleId IdType="pubmed">32386565</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang, L. et al. COVID-19 and multisystem inflammatory syndrome in children and adolescents. Lancet Infect. Dis.20, e276–e288 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7431129</ArticleId><ArticleId IdType="pubmed">32818434</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramcharan, T. et al. Paediatric inflammatory Multisystem Syndrome: temporally Associated with SARS-CoV-2 (PIMS-TS): Cardiac features, management and short-term outcomes at a UK Tertiary Paediatric Hospital. Pediatr. Cardiol.41, 1391–1401 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7289638</ArticleId><ArticleId IdType="pubmed">32529358</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones, V. G. et al. COVID-19 and Kawasaki Disease: Novel Virus and Novel Case. Hosp. Pediatr.10, 537–540 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32265235</ArticleId></ArticleIdList></Reference><Reference><Citation>Verdoni, L. et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet. 395, 1771–1778 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7220177</ArticleId><ArticleId IdType="pubmed">32410760</ArticleId></ArticleIdList></Reference><Reference><Citation>Ecdc Suggested citation: European Centre for Disease Prevention and Control. Paediatric inflammatory multisystem syndrome and SARS-CoV-2 infection in children Paediatric inflammatory multisystem syndrome and SARS-CoV-2 infection in children. (2020).</Citation></Reference><Reference><Citation>Castelli, V., Cimini, A. &amp; Ferri, C. Cytokine storm in COVID-19: when you come out of the storm, you won’t be the same person who walked in. Front. Immunol.11, 2132 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7492381</ArticleId><ArticleId IdType="pubmed">32983172</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, C., Wu, Z., Li, J. W., Zhao, H. &amp; Wang, G. Q. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int. J. Antimicrob. Agents55, 105954 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7118634</ArticleId><ArticleId IdType="pubmed">32234467</ArticleId></ArticleIdList></Reference><Reference><Citation>Coperchini, F., Chiovato, L., Croce, L., Magri, F. &amp; Rotondi, M. The cytokine storm in COVID-19: an overview of the involvement of the chemokine/chemokine-receptor system. Cytokine Growth Factor. Rev.53, 25–32 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7211650</ArticleId><ArticleId IdType="pubmed">32446778</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruber, C. N. et al. Mapping systemic inflammation and antibody responses in Multisystem Inflammatory Syndrome in Children (MIS-C). Cell. 183, 982–995e14 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7489877</ArticleId><ArticleId IdType="pubmed">32991843</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkataraman, A. et al. Plasma biomarker profiling of PIMS-TS, COVID-19 and SARS-CoV2 seropositive children – a cross-sectional observational study from southern India. EBioMedicine 66, (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8016617</ArticleId><ArticleId IdType="pubmed">33813138</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraser, D. D., Patterson, E. K., Daley, M. &amp; Cepinskas, G. Case Report: inflammation and endothelial Injury profiling of COVID-19 Pediatric Multisystem Inflammatory Syndrome (MIS-C). Front. Pediatr.9, 597926 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8060468</ArticleId><ArticleId IdType="pubmed">33898353</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam, C. W. K., Chan, M. H. M. &amp; Wong, C. K. Severe Acute Respiratory Syndrome: Clinical and Laboratory manifestations. Clin. Biochem. Rev.25, 121 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1904416</ArticleId><ArticleId IdType="pubmed">18458712</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, M. et al. CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications. Cytokine Growth Factor. Rev.22, 121–130 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3203691</ArticleId><ArticleId IdType="pubmed">21802343</ArticleId></ArticleIdList></Reference><Reference><Citation>Niu, J. &amp; Kolattukudy, P. E. Role of MCP-1 in cardiovascular disease: molecular mechanisms and clinical implications. Clin. Sci.117, 95–109 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19566488</ArticleId></ArticleIdList></Reference><Reference><Citation>Schönrich, G. &amp; Raftery, M. J. The PD-1/PD-L1 Axis and Virus infections: a delicate balance. Front. Cell. Infect. Microbiol.9, 207 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6584848</ArticleId><ArticleId IdType="pubmed">31263684</ArticleId></ArticleIdList></Reference><Reference><Citation>Karagiannidis, C., Sander, L. E., Mall, M. A. &amp; Busse, R. Incidence and outcomes of SARS-CoV-2-associated PIMS in Germany: a nationwide analysis. Infection. 50, 1627–1629 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9246358</ArticleId><ArticleId IdType="pubmed">35773555</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhedin, S. et al. Risk factors for multisystem inflammatory syndrome in children – A population-based cohort study of over 2 million children. Lancet Reg. Health - Europe19, 100443 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9353212</ArticleId><ArticleId IdType="pubmed">35945929</ArticleId></ArticleIdList></Reference><Reference><Citation>David, J. et al. Impact of SARS-CoV-2 variants on the incidence of paediatric inflammatory multisystem syndrome (PIMS-TS). J. Paediatr. Child. Health. 58, 1901–1903 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9538455</ArticleId><ArticleId IdType="pubmed">36181436</ArticleId></ArticleIdList></Reference><Reference><Citation>Holm, M. et al. Risk and phenotype of Multisystem Inflammatory Syndrome in Vaccinated and unvaccinated Danish children before and during the Omicron Wave. JAMA Pediatr.176, 821–823 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9178498</ArticleId><ArticleId IdType="pubmed">35675054</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter, M. J., Shankar-Hari, M. &amp; Tibby, S. M. Paediatric inflammatory Multisystem Syndrome temporally-Associated with SARS-CoV-2 infection: an overview. Intensive Care Med.47, 90–93 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7556601</ArticleId><ArticleId IdType="pubmed">33057783</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed, M. et al. Multisystem inflammatory syndrome in children: A systematic review. EClinicalMedicine 26, (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7473262</ArticleId><ArticleId IdType="pubmed">32923992</ArticleId></ArticleIdList></Reference><Reference><Citation>Loy, C. J. et al. Nucleic acid biomarkers of immune response and cell and tissue damage in children with COVID-19 and MIS-C. Cell. Rep. Med.10103410.1016/J.XCRM.2023.101034 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10121104</ArticleId><ArticleId IdType="pubmed">37279751</ArticleId></ArticleIdList></Reference><Reference><Citation>Siemińska, I. et al. Mild and asymptomatic COVID-19 convalescents Present Long-Term Endotype of Immunosuppression Associated with Neutrophil subsets possessing Regulatory functions. Front. Immunol.12, 3931 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8511487</ArticleId><ArticleId IdType="pubmed">34659245</ArticleId></ArticleIdList></Reference><Reference><Citation>McArdle, A. J. et al. Treatment of Multisystem Inflammatory Syndrome in Children. N. Engl. J. Med.385, 11–22 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8220965</ArticleId><ArticleId IdType="pubmed">34133854</ArticleId></ArticleIdList></Reference><Reference><Citation>Harwood, R. et al. A national consensus management pathway for paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS): results of a national Delphi process. Lancet Child. Adolesc. Health. 5, 133 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7500943</ArticleId><ArticleId IdType="pubmed">32956615</ArticleId></ArticleIdList></Reference><Reference><Citation>Welzel, T. et al. Methylprednisolone versus intravenous immunoglobulins in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS): an open-label, multicentre, randomised trial. Lancet Child. Adolesc. Health. 7, 238 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9897729</ArticleId><ArticleId IdType="pubmed">36746174</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacina, L., Brábek, J., Fingerhutová, Š., Zeman, J. &amp; Smetana, K. Pediatric Inflammatory Multisystem Syndrome (PIMS) – potential role for cytokines such is IL-6. Physiol. Res.70, 153 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8820574</ArticleId><ArticleId IdType="pubmed">33992044</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong, C. K. et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin. Exp. Immunol.136, 95–103 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1808997</ArticleId><ArticleId IdType="pubmed">15030519</ArticleId></ArticleIdList></Reference><Reference><Citation>Lev, S. et al. Observational cohort study of IP-10’s potential as a biomarker to aid in inflammation regulation within a clinical decision support protocol for patients with severe COVID-19. Berkov E, 10.1371/journal.pone.0245296</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7802954</ArticleId><ArticleId IdType="pubmed">33434221</ArticleId></ArticleIdList></Reference><Reference><Citation>Mól, N. et al. Risk factors of cardiac insufficiency in children with multisystem inflammatory syndrome and COVID-19: a prospective cohort study. Kardiol Pol.79, 1365–1367 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34704607</ArticleId></ArticleIdList></Reference><Reference><Citation>Siedlar, M. et al. Preparations of intravenous immunoglobulins diminish the number and proinflammatory response of CD14 + CD16 + + monocytes in common variable immunodeficiency (CVID) patients. Clin. Immunol.139, 122–132 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21300572</ArticleId></ArticleIdList></Reference><Reference><Citation>Belge, K. U. et al. The proinflammatory CD14 + CD16 + DR + + monocytes are a major source of TNF. J. Immunol.168, 3536–3542 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11907116</ArticleId></ArticleIdList></Reference><Reference><Citation>Dayyani, F. et al. Mechanism of glucocorticoid-induced depletion of human CD14 + CD16 + monocytes. J. Leukoc. Biol.74, 33–39 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12832440</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohri, Y. et al. A young child with pediatric multisystem inflammatory syndrome successfully treated with high-dose immunoglobulin therapy. IDCases 28, (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8969449</ArticleId><ArticleId IdType="pubmed">35382510</ArticleId></ArticleIdList></Reference><Reference><Citation>Brattsand, R. &amp; Linden, M. Cytokine modulation by glucocorticoids: mechanisms and actions in cellular studies. Aliment. Pharmacol. Ther.10 (Suppl 2), 81–90 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8899106</ArticleId></ArticleIdList></Reference><Reference><Citation>Villacis-Nunez, D. S. et al. Short-term outcomes of corticosteroid monotherapy in Multisystem Inflammatory Syndrome in Children. JAMA Pediatr.176, 576–584 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8961405</ArticleId><ArticleId IdType="pubmed">35344042</ArticleId></ArticleIdList></Reference><Reference><Citation>Villarreal, D. O. et al. Molecular adjuvant IL-33 enhances the potency of a DNA vaccine in a lethal challenge model. Vaccine. 33, 4313–4320 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4546882</ArticleId><ArticleId IdType="pubmed">25887087</ArticleId></ArticleIdList></Reference><Reference><Citation>Kak, G., Raza, M. &amp; Tiwari, B. K. Interferon-gamma (IFN-γ): exploring its implications in infectious diseases. Biomol. Concepts. 9, 64–79 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29856726</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz de Morales, J. M. G. et al. Critical role of interleukin (IL)-17 in inflammatory and immune disorders: an updated review of the evidence focusing in controversies. Autoimmun. Rev.19, 102429 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31734402</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinders, M. E. J. et al. Proinflammatory functions of vascular endothelial growth factor in alloimmunity. J. Clin. Invest.112, 1655 (2003).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC281640</ArticleId><ArticleId IdType="pubmed">14660742</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller, A. M. Role of IL-33 in inflammation and disease. J. Inflamm. (Lond)8, 22 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3175149</ArticleId><ArticleId IdType="pubmed">21871091</ArticleId></ArticleIdList></Reference><Reference><Citation>Furci, F. et al. IL-33 and the Cytokine Storm in COVID-19: from a potential immunological relationship towards Precision Medicine. Int. J. Mol. Sci.23, 14532 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9740753</ArticleId><ArticleId IdType="pubmed">36498859</ArticleId></ArticleIdList></Reference><Reference><Citation>Bailly, C., Thuru, X. &amp; Quesnel, B. Soluble programmed death Ligand-1 (sPD-L1): A Pool of circulating proteins implicated in Health and diseases. Cancers (Basel)13, 3034 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8233757</ArticleId><ArticleId IdType="pubmed">34204509</ArticleId></ArticleIdList></Reference><Reference><Citation>Zasada, M. et al. Analysis of PD-1 expression in the monocyte subsets from non-septic and septic preterm neonates. PLoS One12, e018619 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5648248</ArticleId><ArticleId IdType="pubmed">29049359</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin, P. et al. Molecular signatures induced by interleukin-2 on peripheral blood mononuclear cells and T cell subsets. J. Transl Med.4, 26 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1557669</ArticleId><ArticleId IdType="pubmed">16805915</ArticleId></ArticleIdList></Reference><Reference><Citation>Tangye, S. G., Avery, D. T., Deenick, E. K. &amp; Hodgkin, P. D. Intrinsic differences in the proliferation of naive and memory human B cells as a mechanism for enhanced secondary immune responses. J. Immunol.170, 686–694 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12517929</ArticleId></ArticleIdList></Reference><Reference><Citation>Defrance, T. et al. Interleukin 13 is a B cell stimulating factor. J. Exp. Med.179, 135 (1994).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2191343</ArticleId><ArticleId IdType="pubmed">7903680</ArticleId></ArticleIdList></Reference><Reference><Citation>Malefyt, R. D. W. et al. Differential regulation of IL-13 and IL-4 production by human CD8 + and CD4 + Th0, Th1 and Th2 T cell clones and EBV-transformed B cells. Int. Immunol.7, 1405–1416 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7495748</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayry, J. et al. Intravenous immunoglobulin induces proliferation and immunoglobulin synthesis from B cells of patients with common variable immunodeficiency: a mechanism underlying the beneficial effect of IVIg in primary immunodeficiencies. J. Autoimmun.36, 9–15 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">20970960</ArticleId></ArticleIdList></Reference><Reference><Citation>Caucheteux, S. M. et al. IL-1β enhances inflammatory TH2 differentiation. J. Allergy Clin. Immunol.138, 898–901e4 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5014664</ArticleId><ArticleId IdType="pubmed">27212084</ArticleId></ArticleIdList></Reference><Reference><Citation>Heldin, C. H. &amp; Westermark, B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol. Rev.79, 1283–1316 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10508235</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta, A. et al. SARS-CoV-2 infection- induced growth factors play differential roles in COVID-19 pathogenesis. Life Sci.304, 120703 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9188443</ArticleId><ArticleId IdType="pubmed">35700841</ArticleId></ArticleIdList></Reference><Reference><Citation>Santa Cruz, A. et al. Post-acute sequelae of COVID-19 is characterized by diminished peripheral CD8 + β7 integrin + T cells and anti-SARS-CoV-2 IgA response. Nature Communications 2023 14:1 14, 1–14 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10061413</ArticleId><ArticleId IdType="pubmed">36997530</ArticleId></ArticleIdList></Reference><Reference><Citation>Son, M. B. F. et al. Multisystem inflammatory syndrome in children - initial therapy and outcomes. N Engl. J. Med.385, 23–34 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8220972</ArticleId><ArticleId IdType="pubmed">34133855</ArticleId></ArticleIdList></Reference><Reference><Citation>Belhadjer, Z. et al. Addition of corticosteroids to Immunoglobulins is Associated with Recovery of Cardiac function in Multi-inflammatory Syndrome in Children. Circulation. 142, 2282 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7717473</ArticleId><ArticleId IdType="pubmed">33112651</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouldali, N. et al. Association of Intravenous Immunoglobulins plus Methylprednisolone vs immunoglobulins alone with course of Fever in Multisystem Inflammatory Syndrome in Children. JAMA. 325, 855–864 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7851757</ArticleId><ArticleId IdType="pubmed">33523115</ArticleId></ArticleIdList></Reference><Reference><Citation>Henderson, L. A. et al. American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated with SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 3. Arthritis Rheumatol.74, e1–e20 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9011620</ArticleId><ArticleId IdType="pubmed">35118829</ArticleId></ArticleIdList></Reference><Reference><Citation>Aldawas, A. &amp; Ishfaq, M. Multisystem inflammatory syndrome in children (MIS-C) Associated with Coronavirus Disease 2019 (COVID-19). Cureus9 21064 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8826481</ArticleId><ArticleId IdType="pubmed">35165539</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>